Information for Healthcare Professionals

FluMist demonstrated significant reductions in influenza versus the flu shot in a study that included 4,166 children aged 24 months to 59 months during the 2004–2005 influenza season.1; 2
Indicated for children as young as 24 months1
Does not contain thimerosal or other preservatives
FluMist can be administered as soon as it is avaliable
and throughout the flu season, so you can:
- Vaccinate at regularly scheduled visits (well-child
  visits, back-to-school, sports physicals)
- Help vaccine-naïve children receive their
  required 2 doses before flu season starts
Store refrigerated - 0.2 mL

The CDC/ACIP* encourages vaccination to begin as soon as a vaccine is available and to continue throughout the season.3

Learn about the influenza recommendations of the CDC/ACIP.

*Centers for Disease Control and Prevention Advisory Committee on Immunization Practices

Children Flu Vaccine

See the statistics surrounding the importance of vaccinating children early against the flu.

Efficacy in Children

In a large head-to-head influenza vaccine trial in children, FluMist demonstrated significant reductions in influenza versus the flu shot1; 2:^*†

Matched strains: 52.5% reduction in flu cases vs the flu shot (1.4% vs 2.9%)2
Mismatched strains: 54.2% reduction in flu cases vs the flu shot (3.2% vs 7.1%)2
Overall efficacy: 54.4% reduction in flu cases vs the flu shot (4.5% vs 9.8%)2

FluMist achieved these significant reductions against matched and mismatched influenza strains. View the data

* Full study published in The New England Journal of Medicine – February, 2007.
† Study Design: Randomized, double-blind, double-dummy comparison of the relative efficacy of FluMist and TIV intramuscular injection that included children 24 months to 59 months of age, with a 42-day and a 6-month follow-up for safety through the end of the influenza surveillance period for the 2004-2005 influenza season (N=4,166). Vaccine-naïve children in both groups received 2 doses. Comparative efficacy vs culture-confirmed modified CDC influenza-like illness due to matched and mismatched strains [ATP population].
§ The attack rates for FluMist vs the flu shot for all strains circulating during the 2004-2005 flu season were as follows: A/New Caledonia (H1N1) (0.0% vs 1.0%), A/Wyoming (H3N2) (0% vs 0%), A/California-like (H3N2) (1.2% vs 4.9%), matched B/Yamagata lineage (1.4% vs 1.9%, NS), and mismatched B/Yamagata lineage and B/Victoria (2.1% vs 2.3%, NS), respectively.